title: The use of adalimumab for cricoarytenoid arthritis in ankylosing spondylitis--an effective therapy.
abstract: This report describes cartilaginous regeneration in a cricoarytenoid joint affected by spondyloarthropathy using tumor necrosis factor-alpha (TNF-α) blockade, monitored by magnetic resonance (MR) and computed tomography (CT) imaging. This case is interesting for several reasons. It is only the eighth case of destructive ankylosing spondylitis-related cricoarytenoid arthritis published in the English language literature. It describes, for the first time, full recovery of vocal cord mobility following TNF-α blockade. It is also the first case to be published with MR imaging demonstrating regeneration of the cricoarytenoid cartilage following treatment. This case represents a landmark in the treatment of patients presenting with destructive arthritis involving the cricoarytenoid joint.
authors.affiliation: Otolaryngology, Head and Neck Surgery Department, Voice and Swallowing clinic, Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium. gauthier.desuter@uclouvain.be
authors.forename: Gauthier
authors.initials: G
authors.lastname: Desuter
authors.forename: Thierry
authors.initials: T
authors.lastname: Duprez
authors.forename: Caroline
authors.initials: C
authors.lastname: Huart
authors.forename: Quentin
authors.initials: Q
authors.lastname: Gardiner
authors.forename: Gust
authors.initials: G
authors.lastname: Verbruggen
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001168:Arthritis / Q000188:drug therapy*; D001193:Arytenoid Cartilage / Q000502:physiology; D003413:Cricoid Cartilage / Q000502:physiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012038:Regeneration; D013167:Spondylitis, Ankylosing / Q000150:complications*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab